Intervention Review

You have free access to this content

Laquinimod for multiple sclerosis

  1. Dian He1,
  2. Kai Han2,
  3. Xiangdong Gao3,
  4. Shuai Dong3,
  5. Lan Chu1,*,
  6. ZhanHui Feng1,
  7. Shan Wu1

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 6 AUG 2013

Assessed as up-to-date: 1 MAY 2013

DOI: 10.1002/14651858.CD010475.pub2


How to Cite

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.pub2.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Electrophysiology Center, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

*Lan Chu, Department of Neurology, Affiliated Hospital of Guiyang Medical College, No. 28, Gui Yi Street, Guiyang, Guizhou Province, 550004, China. chulan8999@sohu.com.

Publication History

  1. Publication Status: New
  2. Published Online: 6 AUG 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Comi 2012a {published data only}
  • Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. New England Journal of Medicine 2012;366(11):1000-9.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Comi 2008 {published data only}
  • Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371(9630):2085-92.
Comi 2010 {published data only}
  • Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Multiple Sclerosis 2010;16(11):1360-6.
Comi 2011 {published data only}
  • Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Filippi M. Laquinimod slows disability progression and reduces severe relapses in the placebo-controlled phase III ALLEGRO trial for the treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;17 Suppl 10:420-1.
Comi 2012b {published data only}
  • Comi G, Vollmer T, Sorensen PS, Arnold D, Filippi M, Statinov O, et al. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment. Neurology 2012; Vol. 78.
Filippi 2011 {published data only}
  • Filippi M, Rocca M, De Stefano N, Jeffery D, Kappos L, Montalban X, et al. Oral laquinimod reduces MRI markers suggestive of irreversible tissue damage in RRMS: results from ALLEGRO, a placebo-controlled phase III trial. Multiple Sclerosis 2011;17 Suppl 10:146.
Polman 2005b {published data only}
  • Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64(6):987-91.
Vollmer 2012 {published data only}
  • Vollmer T, Comi G, Sorensen PS, Arnold D, Filippi M, Statinova O, et al. Clinical efficacy of laquinimod for the treatment of multiple sclerosis; pooled analyses from the ALLEGRO and BRAVO phase III trials. Neurology 2012; Vol. 78.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Vollmer 2011 {unpublished data only}
  • Vollmer TL, Soelberg Sorensen P, Arnold DL, on behalf of the BRAVO study. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;17:S507-24, Abstract 148.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
NCT01707992 {unpublished data only}
  • The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO). http://www.clinicaltrials.gov/ct2/show/NCT01707992 (Accessed 10 July 2013).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Aharoni 2012
  • Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2012;251(1-2):14-24.
Alonso 2008
Barkhof 2009
Brunmark 2002
  • Brunmark C, Runström A, Ohlsson L, Sparre B, Brodin T, Aström M, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2002;130(1-2):163-72.
Brück 2011
  • Brück W, Wegner C. Insight into the mechanism of laquinimod action. Journal of the Neurological Sciences 2011;306(1-2):173-9.
Brück 2012
  • Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathology 2012;124(3):411-24.
Cadavid 2009
  • Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal of Neurology, Neurosurgery, and Psychiatry 2009;80(12):1337-43.
Confavreux 2006
Fernández 2011
Fernández 2012
  • Fernández Ó, Álvarez-Cermeño JC, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Revista de Neurologia 2012;54(11):677-91.
Fox 2012
  • Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Current Opinion in Neurology 2012;25 Suppl 1:11-9.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org, The Cochrane Collaboration, 2011.
Hulst 2011
Jennum 2012
  • Jennum P, Wanscher B, Frederiksen J, Kjellberg J. The socioeconomic consequences of multiple sclerosis: a controlled national study. European Neuropsychopharmacology 2012;22(1):36-43.
Karampampa 2012
  • Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):e11-25.
Kurtzke 1983
  • Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
Lidster 2012
  • Lidster K, Baker D. Optical coherence tomography detection of neurodegeneration in multiple sclerosis. Current Drug Targets-CNS & Neurological Disorders 2012;11(5):518-27.
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
McDonald 2001
Mishra 2012
  • Mishra MK, Wang J, Silva C, Mack M, Yong VW. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. The American Journal of Pathology 2012;181(2):642-51.
Naci 2010
  • Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28(5):363-79.
National MS Society 2009
  • National MS Society. Who gets MS?. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-aboutms/who-gets-ms/index.aspx (Accessed 29 November 2012).
Oleen-Burkey 2012
Pike 2012
  • Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurology 2012;12(1):94.
Polman 2005a
Polman 2011
Poser 1983
Preiningerova 2009
Review Manager 2012
  • Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Schulze-Topphoff 2012
  • Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLOS One 2012;7(3):e33797.
Shirani 2012
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56.
Thöne 2012
  • Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. The American Journal of Pathology 2012;180(1):267-74.
Toubi 2012
  • Toubi E, Nussbaum S, Staun-Ram E, Snir A, Melamed D, Hayardeny L, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. Journal of Neuroimmunology 2012;251(1-2):45-54.
Tullman 2004
Tuvesson 2005
  • Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegård J. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metabolism and Disposition 2005;33(6):866-72.
van den Elskamp 2010
  • van den Elskamp IJ, Boden B, Dattola V, Knol DL, Filippi M, et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology 2010;52(10):875-81.
Wegner 2010
  • Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2010;227(1-2):133-43.
Yang 2004
  • Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. Journal of Neuroimmunology 2004;156(1-2):3-9.
Zivadinov 2012
  • Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience (Elite Edition) 2012;4:1496-504.
Zou 2002
  • Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002;42(5):731-9.